Anti Cd 20 Ocrevus denied for failing step therapy by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for anti cd20 ocrevus are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Applies Step Therapy to Ocrelizumab

Blue Cross Blue Shield plans commonly require patients to try and fail one or more earlier-line disease-modifying therapies (DMTs) before approving coverage for ocrelizumab (Ocrevus) — a requirement known as step therapy or "fail-first." The rationale is cost management: the plan requires documented evidence that less expensive alternatives were tried and were inadequate before authorizing the higher-cost biologic. For patients with certain MS subtypes or disease characteristics, however, early use of a high-efficacy therapy may be clinically important, and the step-therapy requirement may be medically inappropriate for that individual.

## Why This Denial Is Appealable

Step-therapy denials are adverse benefit determinations subject to your full appeal rights under ACA §2719 and ERISA §503. Many states have enacted step-therapy reform laws that require insurers to grant exceptions when step therapy is not clinically appropriate — check whether your state's law applies to your plan type. You have the right to an internal appeal and, if upheld, independent external review by a certified IRO within approximately four months of the adverse determination (verify your exact deadline). Expedited review is available when delay poses a serious health risk.

## Your Appeal Timeline

1. Request the denial letter and the plan's step-therapy protocol — obtain the exact list of required prior therapies and the criteria for an exception. 2. Identify which steps have been completed and which, if any, the prescriber believes are clinically inappropriate to attempt. 3. File an internal appeal or step-therapy exception request — these are distinct pathways on some plans; ask BCBS which applies. 4. Escalate to external review if the internal appeal is denied; note any applicable state step-therapy law in the escalation.

## Documentation to Gather

• Prior-therapy history: for each DMT the plan requires, provide chart records showing the drug name, start and end dates, clinical response (relapse frequency, MRI activity, functional status), and the reason for discontinuation.
• Contraindication or intolerance records: if the patient cannot safely try a required step drug, provide the specific chart notes, lab results, or subspecialty consultations that document that fact.
• Prescriber exception letter: the neurologist should address each required step therapy directly, explain why it is not appropriate for this patient's specific disease course and clinical situation, and articulate why ocrelizumab is the medically necessary choice at this point in care.
• Disease severity and urgency evidence: MRI reports showing active lesions or progression, clinical notes documenting relapse frequency or disability accumulation, and any evidence that delay of high-efficacy therapy poses meaningful risk for this patient.
• Applicable guideline reference: a citation to the relevant neurology guideline organization supporting early high-efficacy therapy in the patient's clinical context, without quoting specific statistics.

## Criteria-Mapping Structure

Obtain BCBS's step-therapy protocol and map each step against the chart record:

| Required Step Drug | Trial Documented? | Outcome / Reason Inadequate | Supporting Document | |---|---|---|---| | [Drug A from policy] | Yes / No | [Outcome or contraindication] | Chart note, [Date] | | [Drug B from policy] | Yes / No | [Outcome or contraindication] | Chart note, [Date] |

Address any step not completed by documenting the specific clinical reason it was skipped. A structured, evidence-anchored response gives both the internal reviewer and any external IRO the clearest possible path to approving the exception.